Galderma has agreed to acquire ZO Skin Health for an enterprise value of USD 1.5 billion (EUR 1.3 billion), the Swiss skincare group announced on Wednesday, October 14.

The deal values the California-based dermatological skincare company at roughly ten digits in an all-cash transaction. Galderma will acquire 100% of ZO Skin Health from its shareholders, a seller group that includes funds managed by investment firm Blackstone and members of the Obagi family.

The acquisition strengthens Galderma's position in medical skincare, a segment where physician-dispensed and clinic-channel brands have drawn sustained buyer interest. The price tag of USD 1.5 billion sets a clear benchmark for what strategic buyers will pay for established medical skincare portfolios.

Who is selling, and on what terms?

Galderma signed the agreement to purchase the entire company in cash. Blackstone-managed funds and the Obagi family exit their positions through the transaction. The structure is straightforward: 100% of shares, all cash, no disclosed earn-out or equity component.

The enterprise value of USD 1.5 billion converts to approximately EUR 1.3 billion. The announcement came on October 14.

For procurement and formulation teams, an all-cash exit by private equity is the detail that matters. It removes uncertainty around deal financing and points to a clean closing path, subject to standard regulatory clearances.

What does the deal mean for medical skincare?

Galderma, headquartered in Switzerland, already operates across dermatological skincare and injectable aesthetics. Adding ZO Skin Health extends that footprint with a US-based, dermatology-rooted brand built by the Obagi family lineage.

The transaction signals three things for the trade:

• Strategic buyers will pay premium multiples for clinic-channel skincare brands with physician credibility.
• Private equity holders see medical skincare as a mature exit market, not a hold-and-build one.
• Consolidation pressure will likely intensify for independent dermatological brands competing against Galderma's enlarged portfolio.

For clinics and aesthetic practitioners, the practical question is product continuity. Ownership changes at this scale rarely disrupt treatment menus immediately, but distribution terms, pricing structures and bundle programs often get revisited in the quarters after closing.

Why USD 1.5 billion matters

The figure anchors the story. An enterprise value of USD 1.5 billion places ZO Skin Health among the more valuable standalone medical skincare assets to change hands in recent years, and it does so in an all-cash structure that signals buyer confidence.

Galderma's willingness to fund the purchase entirely in cash, buying out Blackstone and the Obagi family in full, tells the market that the Swiss group expects durable returns from the medical skincare category rather than a financial re-engineering play.

The takeaway: Galderma has paid USD 1.5 billion to consolidate its medical skincare position, and every independent brand in the segment now has a clearer reference price.

What comes next

Watch for the closing timeline. Galderma announced the agreement on October 14; the transaction will now move through regulatory review before completion. The next data points to follow are the closing date, any disclosure on ZO Skin Health's revenue or growth profile at completion, and how Galderma integrates the brand into its dermatology portfolio.